the ring A



is 6-membered aryl or heteroaryl;

n is an integer of from 0 to 3;
m is an integer of from 0 to 2;
p is an integer of from 0 to 3;

each R^1 is independently selected from C1-C6 alkyl; C1-C6 alkoxy; OH; halogen; and R^5R^6N;

R^2 is selected from H and C1-C6 alkyl;

each R^3 is independently selected from C1-C6 alkyl;

each R^4 is independently selected from NO_2; halogen; C1-C6 alkyl and C1-C6 alkoxy;

R^5 and R^6 are independently selected from H and C1-C6 alkyl;

wherein any alkyl is optionally substituted with one or several halogen atoms;

or a pharmaceutically acceptable salt thereof.

In another aspect, a compound of formula (I), as defined herein above, is provided for use in therapy, e.g. for use in the treatment of a viral infection, such as an infection by an influenza virus.

In still another aspect, a pharmaceutical composition is provided, comprising a compound as defined herein above, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient.

In still another embodiment a pharmaceutical composition as defined herein above is provided for use in the treatment of a viral infection, such as an infection by an influenza virus. In another aspect, the use of a pharmaceutical composition as defined above, in the manufacture of a medicament for the treatment of a viral infection is provided. In still another aspect, the use of a compound as defined herein, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of a viral infection is provided.

20. A pharmaceutical composition comprising a compound according any one of the claims 1-18, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient.


21. Use of a~~A~~ pharmaceutical composition according to claim 20, ~~for use~~ in the manufacture of a medicament for the treatment of a viral infection.

22. A ~~pharmaceutical composition~~use according to claim 21, wherein the viral infection is an influenza.

23. Use of a~~A~~ compound according to any one of the claims 1-18, or a pharmaceutically acceptable salt thereof, ~~for use~~ in the manufacture of a medicament for the treatment of a viral infection.

24. A ~~compound~~ use according to claim 23, wherein the viral infection is an influenza.

25. A method of preparing a compound of formula (I)



(I)

wherein

U is C or N;

W is C or N;

X is N, CH, O or NH;

Y is N, CH, O or NH;

Z is C or N;

the ring A



is 6-membered aryl or heteroaryl;

n is an integer of from 0 to 3;

m is an integer of from 0 to 2;

p is an integer of from 0 to 3;

each R^1 is independently selected from C1-C6 alkyl; C1-C6 alkoxy; OH; halogen; and R^5R^6N;

R^2 is selected from H and C1-C6 alkyl;

each R^3 is independently selected from C1-C6 alkyl;


each R^4 is independently selected from NO_2; halogen; C1-C6 alkyl and C1-C6 alkoxy;

R^5 and R^6 are independently selected from H and C1-C6 alkyl;

wherein any alkyl is optionally substituted with one or several halogen atoms;

or a pharmaceutically acceptable salt thereof,

comprising reacting a compound of formula (II)



(II)

wherein the ring A, X, Y, Z, U, W, n, m, p, R^1, R^2, R^3 and R^4 are as defined herein above,

with $P_2S_5 \cdot 2\ C_5H_5N$ as a thionating agent in a liquid solvent medium.

~~26. A method of treatment of a viral infection comprising administering to a vertebrate patient in need thereof a therapeutically effective amount of a compound according to any one of the claims 1-18 or a pharmaceutically acceptable salt thereof.~~

~~27. A method according to claim 26, wherein the viral infection is influenza.~~